HACKENSACK, N.J., Feb. 16, 2017 /PRNewswire/ -- Champions
Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development
and sale of advanced technology solutions and products to
personalize the development and use of oncology drugs, today
announced the addition of new cohorts of PDX models to their
existing TumorBank.
These new models will expand Champions' product line in
hepatocellular cancer, breast cancer, castrate resistant prostate
cancer, head and neck cancer, AML, and non-small cell lung cancer
(including EGFR mutation; ALK/ROS1 positive) PDX models.
These clinically relevant models will be made available to support
oncology drug development programs and translational research for
industry and academic customers. The addition of these
models, with full clinical annotation, increases the
Champions TumorBank to greater than 900 clinically relevant
patient-derived xenograft models.
"Champions continues to invest in building new models that
reflect the evolving standard of care to provide robust model
cohorts for pre-clinical research and clinical trial simulation.
Champions Medical Affairs and Clinical Operations infrastructure,
designed to facilitate research collaborations, allows not only for
new PDX model building but also supports building models
co-clinically to maximize translational learning from early phase
clinical trials," Dr. Angela Davies,
Chief Medical Officer stated.
Ronnie Morris, MD, CEO added, "By
making these models commercially available for translational
studies at Champions, researchers and pharmaceutical companies will
now have access to exclusive animal models integral to drug
development research that have been generally inaccessible in the
past. In keeping with our core goals of growing the depth and
breadth of our TumorBank to accelerate revenue growth, Champions
continues to expand its relevant TumorBank, having added over 160
new and unique models in the past 6 months. These new models
in addition to our large existing TumorBank continue to be a
valuable and cost effective tool for the pharmaceutical industry in
their pre-clinical and clinical drug development research."
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's
TumorGraft® technology platform is a novel approach to
personalizing cancer care based upon the implantation of primary
human tumors in immune deficient mice followed by propagation of
the resulting engraftments, or Champions TumorGrafts, in a manner
that preserves the biological characteristics of the original human
tumor in order to determine the efficacy of a treatment
regimen. The Company uses this technology in conjunction with
related services to offer solutions for pharmaceutical and
biotechnology companies seeking personalized approaches to drug
development that can lower the cost and increase the speed of
developing new drugs. TumorGrafts are procured through agreements
with a number of institutions in the U.S. and overseas as well as
through Champions' Personalized Oncology Solutions business, in
which results help guide the development of personalized treatment
plans for individual patients.
For more information, visit Champions Oncology, Inc's website
(www.championsoncology.com)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-announces-new-collection-of-patient-derived-xenograft-pdx-models-available-for-translational-research-300408811.html
SOURCE Champions Oncology, Inc.